All Comments by David Holtzman

  1. Alzheimer’s Vaccine: In Some Patients, at Least, It Might Just Work
  2. Amyloid Oligomer Antibody—One Size Fits All?
  3. Apolipoprotein E influences amyloid-beta clearance from the murine periphery.
  4. Amyloid Formation—One Amino Acid Can Make a Difference
  5. The Alzheimer's Vaccination Story, Continued
  6. More Evidence for Dynamic PolyQ Aggregates
  7. Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.
  8. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration.
  9. Mutant Proteins—Is it Quality or Quantity that Counts?
  10. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation.
  11. Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury.
  12. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
  13. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.
  14. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
  15. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins.